Literature DB >> 31175329

Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade.

Tao Wang1, Lik Hang Lee1, Monika Vyas1, Liying Zhang1, Karuna Ganesh2, Canan Firat1, Neil H Segal2, Avni Desai2, Jaclyn F Hechtman1, Peter Ntiamoah1, Martin R Weiser3, Arnold J Markowitz2, Efsevia Vakiani1, David S Klimstra1, Zsofia K Stadler4, Jinru Shia5.   

Abstract

Double somatic mismatch-repair-gene mutation/alteration is a recently recognized molecular mechanism that underlies microsatellite instability-high in some colorectal carcinomas. It remains to be determined whether and how microsatellite instability-high tumors with this molecular defect differ from their counterparts caused by other mechanisms, specifically, Lynch syndrome-associated and MLH1-promoter hypermethylated. In this study, we evaluated the clinical and pathological characteristics of a series of 15 double somatic mutation/alteration-associated microsatellite instability-high colorectal carcinomas identified from our genetics service and 68 such cases reported in the literature. We observed that these cases presented at an age similar to MLH1-promoter hypermethylated (n = 20) and microsatellite-stable (n = 39) cases but older than Lynch syndrome-associated cases (n = 20, p < 0.05). While these tumors simulated other microsatellite instability-high tumors in their prevalent right-sided location, they appeared to differ in TNM stages at presentation (73% stage III/IV versus 25% stage III/IV in other microsatellite instability-high tumors, p = 0.04). Histologically, 40% of them had a dominant solid growth pattern. Inter-tumoral heterogeneity was a striking feature, spanning the spectrum from medullary type (with a tumor-infiltrating-lymphocyte/high-power-field count as high as 59) to conventional-type with only few tumor-infiltrating-lymphocytes (1/high-power-filed). As a group, these tumors seemed less likely to show robustly high lymphocytic infiltration than other microsatellite instability-high tumors (only 20% had ≥10 tumor-infiltrating-lymphocytes/high-power-filed, whereas this rate in Lynch syndrome-associated and MLH1-promoter hypermethylated tumors was 60% and 75%, respectively). Three double somatic mutation/alteration-associated tumors were treated with a PD1/PD-L1 checkpoint inhibitor. While all three had an elevated tumor-mutation-burden (>47 mut/megabase), only one had tumor-infiltrating-lymphocytes >10/high-power-field, yet all three exhibited measurable response. In summary, microsatellite instability-high colorectal carcinomas caused by double somatic mismatch-repair-gene mutation/alteration may have varied clinical and pathological characteristics, and some may have relatively low tumor-infiltrating-lymphocytes; response to immune checkpoint inhibitors can be achieved in this group even when the lymphocytic infiltration is not abundant.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31175329      PMCID: PMC6849386          DOI: 10.1038/s41379-019-0289-6

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  8 in total

1.  Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade.

Authors:  Bjoern Chapuy; Chip Stewart; Andrew J Dunford; Jaegil Kim; Kirsty Wienand; Atanas Kamburov; Gabriel K Griffin; Pei-Hsuan Chen; Ana Lako; Robert A Redd; Claire M Cote; Matthew D Ducar; Aaron R Thorner; Scott J Rodig; Gad Getz; Margaret A Shipp
Journal:  Blood       Date:  2019-12-26       Impact factor: 22.113

2.  Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors.

Authors:  Berbel L M Ykema; Emilie C H Breekveldt; Beatriz Carvalho; Tom van Wezel; Gerrit A Meijer; Martijn Kerst; Michael Schaapveld; Flora E van Leeuwen; Petur Snaebjornsson; Monique E van Leerdam
Journal:  Br J Cancer       Date:  2022-09-10       Impact factor: 9.075

3.  Heterogeneity in the psychosocial and behavioral responses associated with a diagnosis of suspected Lynch syndrome in women with endometrial cancer.

Authors:  Sowmya Jonnagadla; Sharelle L Joseland; Sibel Saya; Nicole den Elzen; Joanne Isbister; Ingrid M Winship; Daniel D Buchanan
Journal:  Hered Cancer Clin Pract       Date:  2022-07-15       Impact factor: 2.164

4.  Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer.

Authors:  Kjersti Elvestad Hestetun; Kristine Aasebø; Nina Benedikte Rosenlund; Yvonne Müller; Olav Dahl; Mette Pernille Myklebust
Journal:  Mod Pathol       Date:  2020-07-31       Impact factor: 7.842

5.  Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies.

Authors:  Monika Vyas; Canan Firat; Jaclyn F Hechtman; Martin R Weiser; Rona Yaeger; Chad Vanderbilt; Jamal K Benhamida; Ajaratu Keshinro; Liying Zhang; Peter Ntiamoah; Marco Gonzalez; Rebecca Andrade; Imane El Dika; Arnold J Markowitz; J Joshua Smith; Julio Garcia-Aguilar; Efsevia Vakiani; David S Klimstra; Zsofia K Stadler; Jinru Shia
Journal:  Fam Cancer       Date:  2020-10-09       Impact factor: 2.446

Review 6.  Lynch Syndrome: Its Impact on Urothelial Carcinoma.

Authors:  Andrea Katharina Lindner; Gert Schachtner; Gennadi Tulchiner; Martin Thurnher; Gerold Untergasser; Peter Obrist; Iris Pipp; Fabian Steinkohl; Wolfgang Horninger; Zoran Culig; Renate Pichler
Journal:  Int J Mol Sci       Date:  2021-01-07       Impact factor: 5.923

Review 7.  Lynch Syndrome: From Carcinogenesis to Prevention Interventions.

Authors:  Donatella Gambini; Stefano Ferrero; Elisabetta Kuhn
Journal:  Cancers (Basel)       Date:  2022-08-24       Impact factor: 6.575

8.  Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.

Authors:  Inken Salewski; Julia Henne; Leonie Engster; Bjoern Schneider; Heiko Lemcke; Anna Skorska; Peggy Berlin; Larissa Henze; Christian Junghanss; Claudia Maletzki
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.